Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis.

Oncoprotein E6 is essential for oncogenesis induced by human papillomaviruses (HPVs). The solution structure of HPV16-E6 C-terminal domain reveals a zinc binding fold. A model of full-length E6 is proposed and analyzed in the context of HPV evolution. E6 appears as a chameleon protein combining a conserved structural scaffold with highly variable surfaces participating in generic or specialized HPV functions. We investigated surface residues involved in two specialized activities of high-risk genital HPV E6: p53 tumor suppressor degradation and nucleic acid binding. Screening of E6 surface mutants identified an in vivo p53 degradation-defective mutant that fails to recruit p53 to ubiquitin ligase E6AP and restores high p53 levels in cervical carcinoma cells by competing with endogeneous E6. We also mapped the nucleic acid binding surface of E6, the positive potential of which correlates with genital oncogenicity. E6 structure-function analysis provides new clues for understanding and counteracting the complex pathways of HPV-mediated pathogenesis.

[1]  K. Vousden,et al.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.

[2]  Charles D Schwieters,et al.  The Xplor-NIH NMR molecular structure determination package. , 2003, Journal of magnetic resonance.

[3]  Wolfgang Mayer,et al.  Structure and transcription of human papillomavirus sequences in cervical carcinoma cells , 1985, Nature.

[4]  M. Cordingley,et al.  Purification and biophysical characterization of a minimal functional domain and of an N-terminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein. , 2001, Biochemistry.

[5]  J. Moroianu,et al.  Nuclear Entry of High-Risk Human Papillomavirus Type 16 E6 Oncoprotein Occurs via Several Pathways , 2003, Journal of Virology.

[6]  A. Hengstermann,et al.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells , 2003, Oncogene.

[7]  S. Krishna,et al.  Molecular interactions of ‘high risk’ human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression , 2003, Journal of Biosciences.

[8]  E. Androphy,et al.  Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells , 1996, Journal of virology.

[9]  L. Banks,et al.  Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6. , 1998, The Journal of general virology.

[10]  P. Lambert,et al.  Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. , 2005, Cancer research.

[11]  H. Pfister.  Chapter 8: Human papillomavirus and skin cancer. , 2003, Journal of the National Cancer Institute. Monographs.

[12]  L. Banks,et al.  Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein , 2005, Oncogene.

[13]  G. Demers,et al.  The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest , 1994, Journal of virology.

[14]  A. Kristjuhan,et al.  p53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication , 1998, Journal of Virology.

[15]  L. Miguet,et al.  1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6 , 2005, Journal of biomolecular NMR.

[16]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[17]  Etienne Weiss,et al.  Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain. , 2003, Biochemistry.

[18]  E. Androphy,et al.  Multiple Functions of Human Papillomavirus Type 16 E6 Contribute to the Immortalization of Mammary Epithelial Cells , 1999, Journal of Virology.

[19]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[20]  Y. Taketani,et al.  Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. , 1995, Virology.

[21]  H. Hausen.  Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .

[22]  C. Chiang,et al.  E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. , 2005, Molecular cell.

[23]  A. Halpern,et al.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy , 1995, Journal of virology.

[24]  E. Weiss,et al.  Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. , 2005, The Journal of general virology.

[25]  Wei Xu,et al.  Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators , 2002, Nature.

[26]  J. Lefèvre,et al.  Formation of soluble inclusion bodies by hpv e6 oncoprotein fused to maltose-binding protein. , 2001, Protein expression and purification.

[27]  S. Cole,et al.  Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. , 1987, Journal of molecular biology.

[28]  A. Gronenborn,et al.  Improving the quality of NMR and crystallographic protein structures by means of a conformational database potential derived from structure databases , 1996, Protein science : a publication of the Protein Society.

[29]  T. Kiyono,et al.  Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. , 2004, Genes & development.

[30]  E. Bonnefoy,et al.  DNA-binding parameters of the HU protein of Escherichia coli to cruciform DNA. , 1994, Journal of molecular biology.

[31]  Miranda Thomas,et al.  The role of the E6-p53 interaction in the molecular pathogenesis of HPV , 1999, Oncogene.

[32]  E. Weiss,et al.  Protein mutagenesis with monodispersity-based quality probing: selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein. , 2002, Protein expression and purification.

[33]  E. Weiss,et al.  Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6. , 2001, Journal of molecular biology.

[34]  C. Chothia.  Principles that determine the structure of proteins. , 1984, Annual review of biochemistry.

[35]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[36]  L. Banks,et al.  Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. , 2004, The Journal of general virology.

[37]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[38]  Gilles Travé,et al.  Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. , 2005, Journal of molecular biology.

[39]  A. Gronenborn,et al.  Determination of three‐dimensional structures of proteins from interproton distance data by hybrid distance geometry‐dynamical simulated annealing calculations , 1988, FEBS letters.

[40]  X. Li,et al.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation , 1996, Journal of virology.

[41]  Miranda Thomas,et al.  HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation , 2004, Oncogene.

[42]  E. Weiss,et al.  Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. , 2003, The Journal of general virology.

[43]  Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. , 2004, The Journal of general virology.

[44]  P. Howley,et al.  The Role of E6AP in the Regulation of p53 Protein Levels in Human Papillomavirus (HPV)-positive and HPV-negative Cells* , 1998, The Journal of Biological Chemistry.

[45]  C. Sawyers,et al.  Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation , 2002, Oncogene.

[46]  D. Wazer,et al.  Human Papillomavirus Type 16 E6-Induced Degradation of E6TP1 Correlates with Its Ability To Immortalize Human Mammary Epithelial Cells , 2001, Journal of Virology.

[47]  M. Scheffner,et al.  Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins , 1993, Molecular and cellular biology.

[48]  A. Beaudet,et al.  Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. , 2003, Virology.

[49]  J. Lefèvre,et al.  A strategy for optimizing the monodispersity of fusion proteins: application to purification of recombinant HPV E6 oncoprotein. , 2001, Protein engineering.

[50]  H. Pfister.  Human papillomavirus and skin cancer , 2003 .

[51]  J. Acker,et al.  Eukaryotic GST fusion vector for the study of protein-protein associations in vivo: application to interaction of ATFa with Jun and Fos. , 1995, BioTechniques.

[52]  D. Pim,et al.  HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6 , 1999, Oncogene.

[53]  K. Gaston,et al.  Contributions in the domain of cancer research: Review¶Human papillomaviruses and their role in cervical cancer , 2001, Cellular and Molecular Life Sciences CMLS.

[54]  P. Howley,et al.  The human E6-AP gene (UBE3A) encodes three potential protein isoforms generated by differential splicing. , 1997, Genomics.

[55]  Miranda Thomas,et al.  Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. , 1994, Oncogene.

[56]  T. Kessis,et al.  Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. , 1995, Virology.

[57]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[58]  J. Lefèvre,et al.  HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions. , 2000, Journal of molecular biology.